Bron: Braniek / Pharming
Kreeg vandaag van Braniek een mail met het antwoord van Pharming m.b.t. de heer Friesen. Met dank aan Braniek dus.
Robert Friesen, formally Chief Scientific Officer at Pharming, has left the company as per end of May 2022. Robert decided to seize the opportunity, and therefore left Pharming, to assume an executive and ownership position in an immunotherapy start-up company.
Please note that changes in the (non-statutory) Executive Committee are normally not announced by way of a separate press release. The appointment last year of a new CSO and a new CMO to succeed the former CMO constituted an organizational change and was exceptionally announced by way of a press release. As usual, the departure of Robert will be mentioned in the section “Operational Highlights” of the next press release for the announcement of the quarterly results.
Although Robert only joined Pharming as on 1 July 2021, Pharming is grateful for his dedication and hard work for our company and wishes him every success in his future endeavors.
Robert’s succession is currently under review.
Robert Friesen commented: “I have enjoyed my time at Pharming and the inspiring cooperation with my team members, my colleagues in the executive committee and all other colleagues within Pharming. Although I am very excited by the foundations that have and are being developed to drive Pharming’s growth, the possibility to embark on the adventure of building an immunotherapy start-up company, feels for me like a unique opportunity that, at this point in my life, I could not afford to miss. I am confident that Pharming will be successful in unlocking its potential to grow further. I wish the company every success in all its ventures.”
We trust to have informed you sufficiently and remain at your disposal in case of further questions.